سعر سيجنيفور 0.6مجم/مل 30 امبول 2026

Signifor 0.6 mg/mL ampoules (pasireotide) for subcutaneous injection, box of 30 ampoules, listed in Egypt under the Novartis scientific office; a somatostatin analogue used for Cushing's disease.

• Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>= 20% of patients): diarrhea, nausea, hyperglycemia, cholelithiasis, headache, abdominal pain, fatigue and diabetes mellitus.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None (the US label lists no contraindications).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypocortisolism: ACTH suppression may lower cortisol; monitor for weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyponatremia or hypoglycemia and consider dose reduction/interruption or short-term glucocorticoid replacement.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hyperglycemia and diabetes: worsening glycemia occurs early in nearly all patients; assess glycemic status before starting, optimise antidiabetic therapy, monitor glucose weekly for the first 2-3 months and after dose increases.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bradycardia and QT prolongation: use with caution in patients with cardiac disease, bradycardia risk or QT-prolongation risk; baseline ECG and correction of hypokalemia/hypomagnesemia before treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs that prolong the QT intervalPossible additive QT prolongation; use with caution.DailyMed (U.S. National Library of Medicine)
• CyclosporinePasireotide may decrease cyclosporine bioavailability; cyclosporine dose adjustment/monitoring may be needed.DailyMed (U.S. National Library of Medicine)
• BromocriptineSomatostatin analogues may increase bromocriptine levels; bromocriptine dose reduction may be necessary.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are insufficient to inform a drug-associated risk; in rabbits, findings indicating developmental delay occurred at exposures below the human exposure at the highest recommended dose. Premenopausal women should be counselled on possible unintended pregnancy, as cortisol reduction may improve fertility.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk or effects on the breastfed infant; pasireotide passes into the milk of lactating rats. Weigh breastfeeding benefits against the mother's need for the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pasireotide: Binds and activates somatostatin receptors (notably SSTR5, frequently over-expressed on corticotroph tumour cells), inhibiting ACTH secretion and thereby reducing cortisol secretion.